Antimicrobial Drugs Advisory Committee

On Thursday, June 9, 2016, the Antimicrobial Drugs Advisory Committee (AMDAC) supported, by a vote of 10-Yes to 5-No, with 1 abstention, the safety and efficacy of Merck’s bezlotoxumab for the proposed indication of the prevention of Clostridium difficile infection (CDI) recurrence in patients aged 18 years and older.